TABLE 3.
Summary of confirmed bacterial infections and patient with AST results, by infection site and pathogen, reported by Egypt, Ethiopia, Madagascar, Malawi, Mali, Mozambique, Nigeria, South Africa, Sudan, Tunisia, Uganda, and Zambia during three in GLASS data calls (2017–2019).
| Infection site | Pathogen | 2017 (n = 6) | 2018 (n = 9) | 2019 (n = 10) |
|---|---|---|---|---|
| Number of patients with confirmed bacterial infection | ||||
| Bloodstream | Acinetobacter spp. | 141 | 1307 | 3264 |
| Escherichia coli | 405 | 1125 | 4053 | |
| Klebsiella pneumoniae | 329 | 481 | 6146 | |
| Salmonella spp. | 122 | 326 | 616 | |
| Staphylococcus aureus | 867 | 1018 | 6006 | |
| Streptococcus pneumoniae | 647 | 896 | 606 | |
| Total | 2511 | 5153 | 20 691 | |
| Urinary tract | E. coli | 6731 | 2351 | 10 162 |
| K. pneumoniae | 1545 | 1172 | 2549 | |
| Total | 8276 | 3523 | 12 711 | |
| Gastroenteric | Salmonella spp. | 83 | 646 | 674 |
| Shigella spp. | 110 | 692 | 807 | |
| Total | 193 | 1338 | 1481 | |
| Genital | Neisseria gonorrhoeae | 413 | 938 | 340 |
| Total | 413 | 938 | 340 | |
| Total | 11 393 | 10 952 | 35 223 | |
| Number of patients with AST results | ||||
| Bloodstream | Acinetobacter spp. | 140 | 486 | 2980 |
| E. coli | 405 | 1125 | 3635 | |
| K. pneumoniae | 329 | 481 | 5540 | |
| Salmonella spp. | 122 | 326 | 568 | |
| S. aureus | 730 | 1018 | 5603 | |
| S. pneumoniae | 481 | 896 | 405 | |
| Total | 2207 | 4332 | 18 731 | |
| Urinary tract | E. coli | 6706 | 2300 | 9343 |
| K. pneumoniae | 1541 | 1161 | 2315 | |
| Total | 8247 | 3461 | 11 658 | |
| Gastroenteric | Salmonella spp. | 83 | 599 | 629 |
| Shigella spp. | 110 | 650 | 759 | |
| Total | 193 | 1249 | 1388 | |
| Genital | N. gonorrhoeae | 413 | 938 | 340 |
| Total | 413 | 938 | 340 | |
| Total | 11 060 | 9980 | 32 117 | |
GLASS, Global Antimicrobial Resistance and Use Surveillance System; AST, Antimicrobial Susceptibility Testing; n, number; spp., species.